Meliglix 25 Mg

Sitagliptin, the active ingredient in Meliglix 25 Mg, is a DPP-4 inhibitor presented as a 25 mg tablet for oral use. It treats type 2 diabetes mellitus in adult patients. GNH USA supplies Meliglix 25 Mg as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sitagliptin is used in the management of type 2 diabetes mellitus, a disorder of glucose metabolism.

Type 2 diabetes mellitus: improves glycemic control as monotherapy or in combination with other antidiabetic agents. Inadequate control on metformin: provides additional glucose‑lowering effect when added to metformin therapy. Weight‑neutral therapy: offers glucose reduction without causing weight gain, suitable for patients where weight gain is a concern.

Adverse reactions may occur with sitagliptin therapy.

Common Side Effects: - Nasopharyngitis: mild upper respiratory symptoms. - Headache: transient mild to moderate pain. - Upper respiratory tract infection: cough, sore throat. - Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: including Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Arthralgia: joint pain that can be disabling.

Before initiating sitagliptin, consider the following precautions.

Renal impairment: dose adjustment may be required based on creatinine clearance. Hepatic impairment: use with caution in patients with moderate liver disease. History of pancreatitis: avoid or monitor closely for recurrence. Concomitant insulin or sulfonylureas: increased risk of hypoglycemia; monitor glucose levels. Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. Store at ambient temperature: keep below 25°C, retain in the original pack, and protect from moisture.

Sitagliptin may interact with other medicines; review the following.

Major Interactions (Avoid): - Insulin secretagogues (e.g., sulfonylureas): heightened risk of hypoglycemia. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase sitagliptin exposure.

Moderate Interactions (Monitor Closely): - Diuretics (e.g., thiazides): possible reduction in glycemic efficacy. - Rifampin: may lower sitagliptin plasma concentrations. - ACE inhibitors: monitor renal function when used together.